LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Kodu・Aktsiate loetelu・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Suletud

SektorTervishoid

14.32 -2.85

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.93

Max

14.74

Põhinäitajad
By Trading Economics
Sissetulek	179M 211M
Müük	3.6M 77M
P/E Sektori keskmine	25.375 66.845
Kasumimarginaal	273.354
Töötajad	128
EBITDA	-9.2M 28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+6.38% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-82M 1.9B
Eelmine avamishind	17.17
Eelmine sulgemishind	14.32

Uudiste sentiment

By Acuity

34%

66%

91 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

8.1 / 8.21 Toetus ja vastupanu

Aurinia Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2025, 09:49 UTC

Kuumad aktsiad

Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir -- WSJ

Võrdlus sarnastega

Hinnamuutus

Aurinia Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

6.38% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 6.38%

Kõrge 17 USD

Madal 15 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Aurinia Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Aurinia Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.1 / 8.21Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

91 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.